Pharmx Technologies Limited

ASX:PHX Stock Report

Market Cap: AU$56.6m

Pharmx Technologies Balance Sheet Health

Financial Health criteria checks 6/6

Pharmx Technologies has a total shareholder equity of A$23.3M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$27.3M and A$4.0M respectively.

Key information

0%

Debt to equity ratio

AU$0

Debt

Interest coverage ration/a
CashAU$2.57m
EquityAU$23.28m
Total liabilitiesAU$3.99m
Total assetsAU$27.27m

Recent financial health updates

Analysis Article • Sep 01

Pharmx Technologies (ASX:PHX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Recent updates

Analysis Article • Sep 01

Pharmx Technologies (ASX:PHX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Feb 12

What Is PharmX Technologies Limited's (ASX:PHX) Share Price Doing?

PharmX Technologies Limited ( ASX:PHX ), is not the largest company out there, but it received a lot of attention from...
Analysis Article • Jul 12

A Look At The Intrinsic Value Of Corum Group Limited (ASX:COO)

Key Insights The projected fair value for Corum Group is AU$0.046 based on 2 Stage Free Cash Flow to Equity Current...
Analysis Article • May 11

At AU$0.044, Is Corum Group Limited (ASX:COO) Worth Looking At Closely?

Corum Group Limited ( ASX:COO ), might not be a large cap stock, but it saw a significant share price rise of over 20...
Analysis Article • Nov 12

Is Now The Time To Put Corum Group (ASX:COO) On Your Watchlist?

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Analysis Article • Apr 29

At AU$0.089, Is It Time To Put Corum Group Limited (ASX:COO) On Your Watch List?

Corum Group Limited ( ASX:COO ), might not be a large cap stock, but it saw a decent share price growth in the teens...
Analysis Article • Mar 02

Corum Group (ASX:COO) Is Posting Healthy Earnings, But It Is Not All Good News

Despite posting strong earnings, Corum Group Limited's ( ASX:COO ) stock didn't move much over the last week. We looked...
Analysis Article • Dec 13

Corum Group Limited (ASX:COO) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Corum Group's (ASX:COO) stock is up by a considerable 96% over the past three months. But the company's key financial...

Financial Position Analysis

Short Term Liabilities: PHX's short term assets (A$7.5M) exceed its short term liabilities (A$3.2M).

Long Term Liabilities: PHX's short term assets (A$7.5M) exceed its long term liabilities (A$765.0K).

Debt to Equity History and Analysis

Debt Level: PHX is debt free.

Reducing Debt: PHX has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PHX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PHX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 12% each year.

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 08:43
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2026/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharmx Technologies Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Caleb WengPAC Partners Securities Pty. Ltd.